Actively Recruiting
FTT PET/CT in Metastatic Prostate Cancer
Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-07-11
30
Participants Needed
1
Research Sites
174 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
CONDITIONS
Official Title
FTT PET/CT in Metastatic Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants will be 18 years of age or older
- Histologically proven prostate carcinoma
- Clinical evidence of metastatic disease with at least one lesion identified on standard imaging (CT, MRI, Bone Scan, FDG or other PET/CT, Ultrasound)
- Considered a candidate for new or changed therapy with PARP inhibitors and/or androgen deprivation therapy and/or chemotherapy
- Willing to provide informed consent and participate according to guidelines
You will not qualify if you...
- Unable to tolerate imaging procedures as judged by the investigator or treating physician
- Any current medical condition or illness that could compromise safety or successful participation based on physician assessment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin Schubert, BA
CONTACT
A
Ashley Veronsky, BA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here